Table 2 TFAP2D immunostaining results and prostate cancer phenotype in all cancers, ERG negative cancers, and ERG positive cancers
TFAP2D IHC result all cancers | TFAP2D IHC result in ERG negative cancers | TFAP2D IHC result in ERG positive cancers | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
n 13545 | negative (%) 24.3 | positive (%) 75.7 | p value | n 4722 | negative (%) 33.2 | positive (%) 66.8 | p value | n 3776 | negative (%) 11.3 | positive (%) 88.7 | p value | |
Tumor stage | ||||||||||||
pT2 | 8569 | 26.6 | 73.4 | < 0.0001 | 3114 | 35.3 | 64.7 | < 0.0001 | 2268 | 11.3 | 88.7 | 0.8159 |
pT3a | 3054 | 21.9 | 78.1 | 982 | 32.4 | 67.6 | 998 | 10.8 | 89.2 | |||
pT3b-4 | 1866 | 17.1 | 82.9 | 612 | 23.2 | 76.8 | 495 | 11.9 | 88.1 | |||
Gleason grade | ||||||||||||
≤ 3 + 3 | 2391 | 31.8 | 68.2 | < 0.0001 | 865 | 42.7 | 57.3 | < 0.0001 | 725 | 14.3 | 85.7 | 0.0256 |
3 + 4 | 7246 | 24.7 | 75.3 | 2530 | 34 | 66 | 2203 | 10.9 | 89.1 | |||
3 + 4 Tert.5 | 648 | 22.8 | 77.2 | 216 | 29.6 | 70.4 | 117 | 11.1 | 88.9 | |||
4 + 3 | 1354 | 18.8 | 81.2 | 518 | 25.3 | 74.7 | 374 | 8.8 | 91.2 | |||
4 + 3 Tert.5 | 988 | 15.9 | 84.1 | 305 | 23.9 | 76.1 | 211 | 7.6 | 92.4 | |||
≥ 4 + 4 | 809 | 18.3 | 81.7 | 284 | 23.6 | 76.4 | 143 | 13.3 | 86.7 | |||
Gleason grade quant | ||||||||||||
3 + 4 ≤ 5% | 1839 | 27.8 | 72.2 | < 0.0001 | 673 | 37.7 | 62.3 | < 0.0001 | 550 | 12.7 | 87.3 | 0.0636 |
3 + 4 6–10% | 1811 | 25.1 | 74.9 | 663 | 34.5 | 65.5 | 582 | 10.3 | 89.7 | |||
3 + 4 11–20% | 1609 | 23.8 | 76.2 | 574 | 34.3 | 65.7 | 488 | 9.4 | 90.6 | |||
3 + 4 21–30% | 825 | 21.6 | 78.4 | 288 | 29.2 | 70.8 | 284 | 9.2 | 90.8 | |||
3 + 4 31–49% | 682 | 22.1 | 77.9 | 256 | 30.9 | 69.1 | 209 | 12 | 88 | |||
4 + 3 50–60% | 564 | 19.5 | 80.5 | 216 | 26.9 | 73.1 | 168 | 8.3 | 91.7 | |||
4 + 3 61–80% | 495 | 17.6 | 82.4 | 206 | 23.8 | 76.2 | 143 | 7.7 | 92.3 | |||
4 + 3 > 80% | 125 | 16 | 84 | 52 | 19.2 | 80.8 | 33 | 12.1 | 87.9 | |||
Lymph node metastasis | ||||||||||||
N0 | 8141 | 23.8 | 76.2 | < 0.0001 | 2725 | 32.6 | 67.4 | < 0.0001 | 2142 | 11.4 | 88.6 | 0.4192 |
N+ | 1032 | 15.6 | 84.4 | 285 | 20.7 | 79.3 | 242 | 13.2 | 86.8 | |||
Preop. PSA level (ng/ml) | ||||||||||||
< 4 | 1624 | 21.6 | 78.4 | 0.0101 | 487 | 30.4 | 69.6 | 0.2017 | 526 | 10.6 | 89.4 | 0.012 |
4–10 | 7988 | 24.2 | 75.8 | 2797 | 33.6 | 66.4 | 2332 | 10.2 | 89.8 | |||
10–20 | 2846 | 24.8 | 75.2 | 1033 | 31.8 | 68.2 | 661 | 14.1 | 85.9 | |||
> 20 | 1008 | 27.1 | 72.9 | 384 | 36.5 | 63.5 | 231 | 15.2 | 84.8 | |||
Surgical margin | ||||||||||||
negative | 10,764 | 24.8 | 75.2 | 0.0045 | 3743 | 33.6 | 66.4 | 0.2278 | 2983 | 11.5 | 88.5 | 0.4099 |
positive | 2732 | 22.2 | 77.8 | 967 | 31.5 | 68.5 | 777 | 10.4 | 89.6 | |||